Stock vs Stock Comparison

Gilead Sciences, Inc. vs Eli Lilly and Company

GILD wins the Tale of the Tape 5–4.

GILD$128.99
LLY$1078.78

🏆 Tale of the Tape

54
GILDLLY
28.9%Profitability (Net Margin)31.7%
18.3xValuation (P/E)39.2x
18.1%Efficiency (ROIC)30.4%
8/9Health (Piotroski F)7/9
4.4Safety (Altman Z)7.8
2.4%Growth (Rev YoY)44.7%
1.02Risk (Sharpe 1Y)0.61
1.61xBalance Sheet (D/E)3.24x
5.05%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.237
252-Day Correlation
0.303
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricGILDLLY
Market Cap$166.9B$985.4B
P/E Ratio18.3x39.2x
Forward P/E14.0x24.8x
P/B7.10x31.65x
Dividend Yield2.44%0.63%
Beta0.330.48

Quantitative Metrics

MetricGILDLLY
DCF Fair Value$190.19$296.11
DCF Upside+36.8%-68.2%
Piotroski F8/97/9
Altman Z4.417.84
Beneish M-2.45-1.91
FCF Yield5.05%0.68%
Net Debt/EBITDA1.1x1.1x
ROIC18.1%30.4%
WACC7.5%7.8%
ROIC – WACC10.6pp22.5pp
Gross Margin78.8%83.0%
Net Margin28.9%31.7%
Rev Growth YoY2.4%44.7%
Sharpe (1Y)1.020.61
Max Drawdown 3Y
FCF Payout Ratio42%90%

GILD Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

GILD found in:

IBB7.35%
XLV3.02%
IYH2.99%
VHT2.63%
HDV2.24%
DGRW1.30%
VFQY1.17%
XBI1.03%
DVY1.01%
QQQ0.84%
MGV0.81%
VIG0.73%
VYM0.68%
VTV0.63%
SCHV0.62%
VFVA0.46%
IWD0.42%
VONV0.36%
ESGV0.35%
QUS0.35%
SCHX0.30%
VFMO0.29%
SCHB0.28%
IVV0.26%
VOO0.26%
SPYV0.26%
SPY0.25%
VONE0.25%
SPLG0.25%
SPYG0.25%
SPTM0.24%
ITOT0.23%
VTI0.23%
RSP0.23%
URTH0.22%
ACWI0.18%
IWF0.17%
VONG0.14%
VT0.14%
ONEO0.13%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

GILD vs LLY: Head-to-Head Analysis

Gilead Sciences, Inc. (GILD) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, GILD leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, GILD generates a return on invested capital (ROIC) of 18.1% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between GILD and LLY is 0.237, indicating low correlation, making them an effective diversification pair in a portfolio context.

GILD appears in 40 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, GILD or LLY?

Our quantitative analysis compares GILD and LLY across nine fundamental dimensions. GILD wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are GILD and LLY correlated?

The 252-day correlation between GILD and LLY is 0.237. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.